TY  - JOUR
AU  - Bisanzi, Simonetta
AU  - Puliti, Donella
AU  - Picozzi, Giulia
AU  - Romei, Chiara
AU  - Pistelli, Francesco
AU  - Deliperi, Annalisa
AU  - Carreras, Giulia
AU  - Masala, Giovanna
AU  - Gorini, Giuseppe
AU  - Zappa, Marco
AU  - Sani, Cristina
AU  - Carrozzi, Laura
AU  - Paci, Eugenio
AU  - Kaaks, Rudolf
AU  - Carozzi, Francesca Maria
AU  - Mascalchi, Mario
TI  - Baseline Cell-Free DNA Can Predict Malignancy of Nodules Observed in the ITALUNG Screening Trial.
JO  - Cancers
VL  - 16
IS  - 12
SN  - 2072-6694
CY  - Basel
PB  - MDPI
M1  - DKFZ-2024-01386
SP  - 2276
PY  - 2024
N1  - #LA:C020#
AB  - The role of total plasma cell-free DNA (cfDNA) in lung cancer (LC) screening with low-dose computed tomography (LDCT) is uncertain. We hypothesized that cfDNA could support differentiation between malignant and benign nodules observed in LDCT. The baseline cfDNA was measured in 137 subjects of the ITALUNG trial, including 29 subjects with screen-detected LC (17 prevalent and 12 incident) and 108 subjects with benign nodules. The predictive capability of baseline cfDNA to differentiate malignant and benign nodules was compared to that of Lung-RADS classification and Brock score at initial LDCT (iLDCT). Subjects with prevalent LC showed both well-discriminating radiological characteristics of the malignant nodule (16 of 17 were classified as Lung-RADS 4) and markedly increased cfDNA (mean 18.8 ng/mL). The mean diameters and Brock scores of malignant nodules at iLDCT in subjects who were diagnosed with incident LC were not different from those of benign nodules. However, 75
KW  - biomarkers (Other)
KW  - cell-free DNA (Other)
KW  - low-dose CT (Other)
KW  - lung cancer (Other)
KW  - prediction (Other)
KW  - screening (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:38927981
C2  - pmc:PMC11201711
DO  - DOI:10.3390/cancers16122276
UR  - https://inrepo02.dkfz.de/record/291412
ER  -